Abstract
Objective Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal manag......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
